SCHEMBL27167058

SCHEMBL27167058

CC(C)(C)OC(=O)Nc1cc(Cl)nc(Cl)c1C=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.43
▸ LCK P06239 3/20 0.39
▸ METAP1 P53582 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ HSP90AB1 P08238 1/20 0.36
▸ CYP17A1 P05093 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ STK17B O94768 1/20 0.35
▸ STK17A Q9UEE5 1/20 0.35
▸ BRD9 Q9H8M2 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 2/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ MAPKAPK2 P49137 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29565827 0.83 KDM4E (0.38) RAB9AKMT2AMEN1NPC1LMNA
SCHEMBL16856891 0.83 KDM4E (0.38) RAB9AKMT2AMEN1NPC1LMNA
SCHEMBL10085201 0.81 ATR (0.55) ATRMETAP1HSP90AA1HSP90AB1CYP17A1
SCHEMBL15831474 0.80 ATR (0.42) ATRLCKHSP90AA1HSP90AB1STK17B
SCHEMBL27141821 0.80 ATR (0.42) ATRLCKMETAP1CYP17A1STK17B
SCHEMBL17113828 0.80 ATR (0.42) ATRLCKCYP17A1STK17BSTK17A
SCHEMBL16427076 0.79 ATR (0.44) ATRLCKMETAP1CYP17A1RAB9A
SCHEMBL1058517 0.79 ALDH1A1 (0.44) ATRLCKRAB9ASTK17BSTK17A
SCHEMBL31248792 0.79 STK17B (0.43) ATRLCKHSP90AA1HSP90AB1CYP17A1
SCHEMBL31664072 0.79 ATR (0.44) ATRLCKSTK17BSTK17ABRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2024-09-19 — — US disclosed
EP-4334295-A2 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Vigil Neuoscience, Inc. (US) 2024-03-13 — — EP disclosed
CN-117597333-A Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use 维吉尔神经科学股份有限公司 2024-02-23 — — CN disclosed
WO-2022236272-A2 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2022-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 ATR 2474/4885LCK 442/4885METAP1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback